These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36134017)

  • 1. Extra-CNS and dural metastases in
    Kleinschmidt-DeMasters BK; Gilani A
    Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and Molecular Characteristics of
    Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
    Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
    Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma,
    Broggi G; Piombino E; Altieri R; Romano C; Certo F; Barbagallo GMV; Vigneri P; Condorelli D; Colarossi L; Colarossi C; Magro G; Tirrò E
    Front Neurol; 2022; 13():823015. PubMed ID: 35222252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
    McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
    Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RT-PCR assay to detect
    Priesterbach-Ackley LP; van Kuik J; Tops BBJ; Lasorella A; Iavarone A; van Hecke W; Robe PA; Wesseling P; de Leng WWJ
    Neurooncol Pract; 2024 Apr; 11(2):142-149. PubMed ID: 38496910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
    Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
    Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
    Gött H; Uhl E
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Gliomas with
    Marastoni E; Mulone D; Barresi V
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730596
    [No Abstract]   [Full Text] [Related]  

  • 12. Polymorphous low-grade neuroepithelial tumor of the young with FGFR3-TACC3 fusion mimicking high-grade glioma: case report and series of high-grade correlates.
    Golub D; Lynch DG; Pan PC; Liechty B; Slocum C; Bale T; Pisapia DJ; Juthani R
    Front Oncol; 2023; 13():1307591. PubMed ID: 38074682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
    Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma.
    Cabezas-Camarero S; Pérez-Alfayate R; Polidura C; Gómez-Ruiz MN; Gil-Martínez L; Casado-Fariñas I; Bartolomé J; Pérez-Segura P
    Neurooncol Adv; 2024; 6(1):vdae139. PubMed ID: 39211518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
    Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
    PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity.
    Agaimy A; Antonescu CR; Bell D; Breimer GE; Dermawan JK; Kester LA; Laco J; Rijken JA; Whaley RD; Stoehr R; Cramer T; Bishop JA
    Virchows Arch; 2024 Oct; ():. PubMed ID: 39387893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
    Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
    Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
    Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
    Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi technology targeting the
    Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
    Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.